Acquiring Company
Ensysce Biosciences
Acquired Company
Cy Biopharma
New YorkManufacturingHardwareFinancial ServicesFinanceFintechLendingBankingBiotechnologyHealth CarePharmaceuticalBiopharmaDescription
Ensysce Biosciences has acquired Cy Biopharma, significantly enhancing its liquidity and pipeline for chronic pain treatments. The deal provides approximately $31 million in net cash and includes strategic adjustments to Ensysce's clinical focus. Importantly, Cy Biopharma’s lead asset has FDA Orphan Drug Designation, positioning it as a key component in Ensysce's development strategy. This acquisition aims to further advance innovative pain management solutions.
Don't miss Ensysce Biosciences's next move
Get an email the moment Ensysce Biosciences makes an acquisition, hires an exec, or expands, usually minutes after it happens.
One email per event. Unsubscribe anytime.
Related People
M&A Insights
Based on deal dataFrequently asked
Who acquired Cy Biopharma?
Cy Biopharma was acquired by Ensysce Biosciences, based in New York. The deal was reported on August 21, 2026. Ensysce Biosciences, based in San Diego, CA is a clinical-stage biotech company using its two novel proprietary technology platforms to develop safer prescription drugs. Ensysce Biosciences is publicly traded (ENSC) and operates in Manufacturing.
When did Ensysce Biosciences acquire Cy Biopharma?
Ensysce Biosciences's acquisition of Cy Biopharma was reported on August 21, 2026. Ensysce Biosciences has acquired Cy Biopharma, significantly enhancing its liquidity and pipeline for chronic pain treatments. The deal provides approximately $31 million in net cash and includes strategic adjustments to Ensysce's clinical focus. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.
What does Cy Biopharma do?
Cy Biopharma is a biopharmaceutical firm developing therapies for pain conditions. They focus on neuroplastogenic approaches to treat chronic pain syndromes. Their lead asset is a neuroplastogenic receptor agonist for complex regional pain syndrome. It is privately held, operating in Biotechnology.
This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.
145 of these a day, filtered to the companies you pick. $29 a month, billed annually, and if it does not pay for itself in a year we refund it.